



(51) International Patent Classification:

G01N 33/564 (2006.01) C07K 16/18 (2006.01)
A61K 39/395 (2006.01) A61P 29/00 (2006.01)
A61P 13/12 (2006.01)

(21) International Application Number:

PCT/US2024/038183

(22) International Filing Date:

16 July 2024 (16.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/527,123 17 July 2023 (17.07.2023) US

(71) Applicant: Q32 BIO INC. [US/US]; 830 Winter Street,
Waltham, MA 02451 (US).

(72) Inventors: WAWERSIK, Stefan; c/o Q32 Bio Inc., 830
Winter Street, Waltham, MA 02451 (US). VIOLETTE,
Shelia Marie; c/o Q32 Bio Inc., 830 Winter Street,
Waltham, MA 02451 (US). MORGAN, Jennifer; c/o
Q32 Bio Inc., 830 Winter Street, Waltham, MA 02451
(US). RYAN, Sarah; c/o Q32 Bio Inc., 830 Winter Street,
Waltham, MA 02451 (US). GALAND, Claire; c/o Q32 Bio
Inc., 830 Winter Street, Waltham, MA 02451 (US). THUR-

MAN, Joshua M.; c/o Q32 Bio Inc., 830 Winter Street,
Waltham, MA 02451 (US).


(74) Agent: LU, Yu et al.; McCarter & English, LLP, 265
Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: TARGETED TREATMENT OF COMPLEMENT-MEDIATED DISEASE THROUGH LOCAL COMPLEMENT IN-
HIBITION BASED ON URINARY UC5b-9 DETECTION

FIG. 1



(57) Abstract: Provided is the use of urinary C5b-9 (uC5b-9) as a highly accurate and superior biomarker well correlated with comple-
ment activity in local tissues affected by complement-mediated diseases (e.g., those with a kidney damage component). The biomarker
is useful, for example, in treating and/or monitoring such complement-mediated diseases, using complement inhibitors targeted to such
local tissues affected by the diseases, without systemic complement inhibition.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

03 April 2025 (03.04.2025)